论文部分内容阅读
目的:探讨采用脊髓电刺激(SCS)治疗神经病理性疼痛(NP)的测试效果及其影响因素。方法:回顾性分析2012年1月至2019年12月首都医科大学宣武医院功能神经外科采用SCS治疗的81例NP患者的临床资料。对所有患者选择双极刺激模式，频率为30～60 Hz，脉宽为180～260 μs，电压为0.5～2.0 V。以疼痛改善率作为SCS测试是否有效的主要评估指标，计算公式为：疼痛改善率＝[术前视觉模拟评分(VAS)-术后VAS] /术前VAS×100%；其中疼痛改善率>50%为测试有效，≤50%为测试无效。采用单因素和多因素logistic回归分析法分析影响NP患者SCS测试效果的危险因素。结果:81例患者均成功植入电极。81例患者术后疼痛改善率为(45.9±2.9)%；术后VAS为(4.5±2.5)分，较术前[(8.3±1.2)分]显著下降(n t＝13.67，n P0.05)，而疼痛部位是SCS测试效果的影响因素(n P<0.05)。进一步多因素logistic回归分析结果显示，疼痛位于下肢是影响SCS测试效果的保护因素(n OR＝3.14，95%n CI：1.26～7.83，n P＝0.013)。n 结论:采用SCS治疗NP的测试有效率较高；疼痛位于四肢，特别是下肢的NP患者测试效果较好。“,”Objective:To investigate the therapeutic effect of spinal cord stimulation (SCS) screening trial on neuropathic pain (NP) and its influencing factors.Methods:A retrospective analysis was conducted on the clinical data of 81 patients with NP who underwent SCS screening trial at Department of Functional Neurosurgery, Xuanwu Hospital of Capital Medical University from January 2012 to December 2019. Bipolar mode was employed in all patients with the frequency of 30-60 Hz, pulse width of 180-260 μs, and voltage of 0.5-2.0 V. The rate of pain improvement was used as an indicator of whether the SCS screening trail was effective and calculated as [preoperative visual analogue scale (VAS) score-postoperative VAS score]/preoperative VAS score ×100%. Univariate and multivariate logistic regression analyses were used to analyze the factors affecting the efficacy of SCS screening trail.Results:A total of 81 patients were successfully implanted with SCS electrode. The overall postoperative pain relief rate was (45.9±2.9)%. Postoperative VAS score was 4.5 ± 2.5, which was significantly lower than preoperative VAS score (8.3±1.2) (n t=13.67, n P0.05), while the pain territory was the factor affecting the efficacy of SCS trial (n P<0.05). Further multivariate analysis showed that lower limb pain was a positive factor for the efficacy of SCS test (n OR=3.14, 95%n CI: 1.26-7.83, n P=0.013).n Conclusions:The overall effective rate of SCS trial in the treatment of NP seems relatively high. Patients with pain in the limb(s), particularly lower limb(s), may have a better trial outcome.